You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLevorphanol
Accession NumberDB00854  (APRD00764)
TypeSmall Molecule
GroupsApproved
DescriptionA narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection. [PubChem]
Structure
Thumb
Synonyms
Levorfanol
Levorfanolo
Lévorphanol
Levorphanol
Levorphanolum
External Identifiers
  • Dea No. 9220
  • Dea No. 9733
  • Ro 1-5431
Approved Prescription ProductsNot Available
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Levorphanol Tartratetablet2 mg/1oralRoxane Laboratories, Inc2000-03-31Not applicableUs
Levorphanol Tartratetablet2 mg/1oralSentynl Therapeutics, Inc.2015-05-28Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AromaroneNot Available
CetarinNot Available
LemoranNot Available
Levo-DromoranValeant Pharmaceuticals International
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Levorphanol tartrate
ThumbNot applicableDBSALT000935
Categories
UNII27618J1N2X
CAS number77-07-6
WeightAverage: 257.3706
Monoisotopic: 257.177964363
Chemical FormulaC17H23NO
InChI KeyInChIKey=JAQUASYNZVUNQP-USXIJHARSA-N
InChI
InChI=1S/C17H23NO/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17/h5-6,11,14,16,19H,2-4,7-10H2,1H3/t14-,16+,17+/m0/s1
IUPAC Name
(1R,9R,10R)-17-methyl-17-azatetracyclo[7.5.3.0¹,¹⁰.0²,⁷]heptadeca-2(7),3,5-trien-4-ol
SMILES
[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Benzazocine
  • Tetralin
  • Aralkylamine
  • Benzenoid
  • Piperidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the management of moderate to severe pain or as a preoperative medication where an opioid analgesic is appropriate
PharmacodynamicsLevorphanol is a potent synthetic opioid analgesic indicated for the management of moderate to severe pain or as a preoperative medication where an opioid analgesic is appropriate. Levorphanol is similar to morphine in its actions, however it is up to 8 times more potent than morphine. Levorphanol produces a degree of respiratory depression similar to that produced by morphine at equianalgesic doses, and like many mu-opioid drugs, levorphanol produces euphoria or has a positive effect on mood in many individuals.
Mechanism of actionLike other mu-agonist opioids it is believed to act at receptors in the periventricular and periaqueductal gray matter in both the brain and spinal cord to alter the transmission and perception of pain.
Related Articles
AbsorptionLevorphanol is well absorbed after PO administration with peak plasma concentrations occurring approximately 1 hour after dosing.
Volume of distribution
  • 10 to 13 L/kg
Protein binding40%
Metabolism

Levorphanol is extensively metabolized in the liver and is eliminated as the glucuronide metabolite.

Route of eliminationNot Available
Half life11-16 hours
Clearance
  • 0.78 to 1.1 L/kg/hr
ToxicityLD50=150 mg/kg (orally in rats). Signs of overdose include nausea, emesis, dizziness, respiratory depression, hypotension, urinary retention, cardiac arrhythmias, allergic reactions, skin rash, and uticaria.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Levorphanol Action PathwayDrug actionSMP00673
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9924
Blood Brain Barrier+0.9953
Caco-2 permeable+0.8767
P-glycoprotein substrateSubstrate0.8217
P-glycoprotein inhibitor INon-inhibitor0.7866
P-glycoprotein inhibitor IINon-inhibitor0.935
Renal organic cation transporterInhibitor0.7666
CYP450 2C9 substrateNon-substrate0.7467
CYP450 2D6 substrateSubstrate0.78
CYP450 3A4 substrateSubstrate0.7112
CYP450 1A2 substrateNon-inhibitor0.6437
CYP450 2C9 inhibitorNon-inhibitor0.9139
CYP450 2D6 inhibitorInhibitor0.7703
CYP450 2C19 inhibitorNon-inhibitor0.8908
CYP450 3A4 inhibitorNon-inhibitor0.8856
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9051
Ames testNon AMES toxic0.5661
CarcinogenicityNon-carcinogens0.9694
BiodegradationNot ready biodegradable0.9681
Rat acute toxicity2.9455 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6841
hERG inhibition (predictor II)Non-inhibitor0.5153
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Valeant pharmaceuticals international
  • Roxane laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral2 mg/1
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point198-199 °CPhysProp
water solubility1840 mg/LNot Available
logP3.11HANSCH,C ET AL. (1995)
pKa9.58SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.173 mg/mLALOGPS
logP3.29ALOGPS
logP2.9ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)10.46ChemAxon
pKa (Strongest Basic)9.66ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area23.47 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity78.08 m3·mol-1ChemAxon
Polarizability29.84 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4i-5930000000-4593c62f1e2a0579a248View in MoNA
References
Synthesis Reference

Joseph P. Haar, “Process for the Production of Levorphanol and Related Compounds.” U.S. Patent US20080146805, issued June 19, 2008.

US20080146805
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (5.23 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Levorphanol.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Levorphanol.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Levorphanol is combined with 7-Nitroindazole.
AcepromazineAcepromazine may increase the hypotensive activities of Levorphanol.
AcepromazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Aceprometazine.
AcetazolamideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Acetazolamide.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Levorphanol.
adipiplonThe risk or severity of adverse effects can be increased when Levorphanol is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Levorphanol.
AlimemazineAlimemazine may increase the hypotensive activities of Levorphanol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levorphanol.
AlvimopanThe risk or severity of adverse effects can be increased when Levorphanol is combined with Alvimopan.
AmilorideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Amiloride.
AmisulprideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Amitriptyline.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Levorphanol which could result in a higher serum level.
AmobarbitalThe risk or severity of adverse effects can be increased when Levorphanol is combined with Amobarbital.
AmoxapineLevorphanol may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Levorphanol.
AmperozideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Levorphanol.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Levorphanol.
AripiprazoleThe risk or severity of adverse effects can be increased when Levorphanol is combined with Aripiprazole.
ArticaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Asenapine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Levorphanol.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Levorphanol.
AzaperoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Azaperone.
AzelastineLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Levorphanol.
AzosemideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Levorphanol is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Levorphanol is combined with Barbital.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Levorphanol.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Bendroflumethiazide.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Levorphanol.
BenzocaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Benzocaine.
BenzphetamineBenzphetamine may increase the analgesic activities of Levorphanol.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Levorphanol is combined with Benzyl alcohol.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Levorphanol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Levorphanol is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.
BrimonidineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Brotizolam.
BumetanideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Levorphanol.
BuprenorphineBuprenorphine may decrease the analgesic activities of Levorphanol.
BuprenorphineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Levorphanol.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levorphanol.
ButacaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Levorphanol is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Levorphanol is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Levorphanol is combined with Butethal.
ButorphanolButorphanol may decrease the analgesic activities of Levorphanol.
ButorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Butorphanol.
Canrenoic acidThe risk or severity of adverse effects can be increased when Levorphanol is combined with Canrenoic acid.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Levorphanol.
CarbinoxamineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Levorphanol is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Levorphanol.
ChlormezanoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chloroprocaine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Levorphanol.
ChlorphentermineChlorphentermine may increase the analgesic activities of Levorphanol.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Levorphanol.
ChlorpromazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Levorphanol.
CitalopramLevorphanol may increase the serotonergic activities of Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Levorphanol is combined with clomethiazole.
ClomipramineLevorphanol may increase the serotonergic activities of Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Levorphanol.
ClonazepamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levorphanol.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Levorphanol.
CocaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Levorphanol.
ConivaptanThe risk or severity of adverse effects can be increased when Levorphanol is combined with Conivaptan.
CyclizineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cyclobenzaprine.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Levorphanol.
CyclothiazideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levorphanol.
DapoxetineLevorphanol may increase the serotonergic activities of Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Levorphanol.
deramciclaneThe risk or severity of adverse effects can be increased when Levorphanol is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Levorphanol.
DesmopressinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Desmopressin.
DetomidineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Levorphanol.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Levorphanol.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Levorphanol.
DextromoramideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Levorphanol.
DezocineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Levorphanol.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Levorphanol.
DifenoxinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.
DoxylamineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Levorphanol is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Levorphanol.
DrospirenoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levorphanol.
EcgonineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Levorphanol is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Levorphanol is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Efonidipine.
EluxadolineLevorphanol may increase the constipating activities of Eluxadoline.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Levorphanol.
EntacaponeThe risk or severity of adverse effects can be increased when Levorphanol is combined with Entacapone.
EplerenoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Eplerenone.
EscitalopramLevorphanol may increase the serotonergic activities of Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levorphanol.
Etacrynic acidThe risk or severity of adverse effects can be increased when Levorphanol is combined with Etacrynic acid.
EthanolLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Levorphanol.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levorphanol.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Levorphanol.
EthosuximideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Levorphanol.
EtoperidoneLevorphanol may increase the serotonergic activities of Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fencamfamine.
FenfluramineLevorphanol may increase the serotonergic activities of Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levorphanol.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Levorphanol.
FexofenadineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Flunitrazepam.
FluoxetineLevorphanol may increase the serotonergic activities of Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Flupentixol.
FluphenazineFluphenazine may increase the hypotensive activities of Levorphanol.
FluphenazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Levorphanol.
FluspirileneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fluticasone Propionate.
FluvoxamineLevorphanol may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Levorphanol.
FosphenytoinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fospropofol.
FurosemideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Furosemide.
GabapentinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Levorphanol is combined with gabapentin enacarbil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Levorphanol.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Levorphanol is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Glutethimide.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Levorphanol.
GuanfacineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Levorphanol.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Levorphanol.
HalothaneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Levorphanol.
HexobarbitalThe risk or severity of adverse effects can be increased when Levorphanol is combined with Hexobarbital.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Levorphanol.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Hydrocodone.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Levorphanol.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Levorphanol.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.
HydroxyzineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Levorphanol.
IloperidoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Imipramine.
IndalpineLevorphanol may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Indapamide.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Levorphanol.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Levorphanol.
IsosorbideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Isosorbide.
KetamineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ketobemidone.
KW-3902The risk or severity of adverse effects can be increased when Levorphanol is combined with KW-3902.
LamotrigineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Levorphanol is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Levomethadyl Acetate.
LevomilnacipranLevorphanol may increase the serotonergic activities of Levomilnacipran.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Levorphanol.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Levorphanol.
LithiumThe risk or severity of adverse effects can be increased when Levorphanol is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Levorphanol is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Levorphanol.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Levorphanol.
Lu AA21004Levorphanol may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Levorphanol.
LurasidoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Maprotiline.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Levorphanol.
MeclizineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Levorphanol is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Melperone.
MephentermineMephentermine may increase the analgesic activities of Levorphanol.
MepivacaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levorphanol.
MersalylThe risk or severity of adverse effects can be increased when Levorphanol is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Levorphanol.
MesoridazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Levorphanol.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methadyl Acetate.
MethamphetamineMethamphetamine may increase the analgesic activities of Levorphanol.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Levorphanol.
MethapyrileneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Levorphanol.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Levorphanol.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methyclothiazide.
Methylene blueMethylene blue may increase the hypotensive activities of Levorphanol.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levorphanol.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Levorphanol.
MetolazoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Metolazone.
MetyrosineLevorphanol may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Levorphanol.
MilnacipranLevorphanol may increase the serotonergic activities of Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.
MirtazapineLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Levorphanol.
MolindoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Molindone.
MoricizineMoricizine may increase the hypotensive activities of Levorphanol.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Levorphanol.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Levorphanol.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.
NabiloneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Nabilone.
NalbuphineNalbuphine may decrease the analgesic activities of Levorphanol.
NalbuphineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Nalbuphine.
NaltrexoneThe therapeutic efficacy of Levorphanol can be decreased when used in combination with Naltrexone.
NitrazepamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Levorphanol.
OlanzapineLevorphanol may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Levorphanol.
OlopatadineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Levorphanol is combined with Opium.
OrphenadrineLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Levorphanol.
OsanetantThe risk or severity of adverse effects can be increased when Levorphanol is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levorphanol.
OxprenololThe risk or severity of adverse effects can be increased when Levorphanol is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Oxybuprocaine.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Levorphanol.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levorphanol.
OxymorphoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Levorphanol.
PaliperidoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Paliperidone.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Levorphanol.
ParaldehydeLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Levorphanol.
ParoxetineLevorphanol may increase the serotonergic activities of Paroxetine.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Levorphanol.
PentazocinePentazocine may decrease the analgesic activities of Levorphanol.
PentazocineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Levorphanol.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Levorphanol.
PerampanelThe risk or severity of adverse effects can be increased when Levorphanol is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Levorphanol is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Levorphanol.
PerphenazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Levorphanol.
PhenobarbitalThe risk or severity of adverse effects can be increased when Levorphanol is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Phenoxyethanol.
PhenterminePhentermine may increase the analgesic activities of Levorphanol.
PhenytoinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Levorphanol.
PipotiazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Levorphanol.
PiretanideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Piretanide.
PizotifenThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pizotifen.
PolythiazideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pomalidomide.
PotassiumThe risk or severity of adverse effects can be increased when Levorphanol is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Potassium Citrate.
PramipexoleLevorphanol may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Levorphanol.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Levorphanol.
PrimidoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Levorphanol.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Levorphanol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Levorphanol.
PromazinePromazine may increase the hypotensive activities of Levorphanol.
PromazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Levorphanol.
PromethazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Levorphanol.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Levorphanol.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Levorphanol.
PropoxycaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Levorphanol is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Quetiapine.
QuinethazoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Quinethazone.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Levorphanol.
RamelteonThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ramelteon.
RamosetronLevorphanol may increase the constipating activities of Ramosetron.
RemifentanilThe risk or severity of adverse effects can be increased when Levorphanol is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levorphanol.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Levorphanol.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Levorphanol.
RomifidineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Romifidine.
RopiniroleLevorphanol may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Levorphanol.
RotigotineLevorphanol may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Levorphanol.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Levorphanol is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levorphanol.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Levorphanol.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levorphanol.
SertindoleThe risk or severity of adverse effects can be increased when Levorphanol is combined with Sertindole.
SertralineLevorphanol may increase the serotonergic activities of Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Sodium oxybate.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Levorphanol.
SpironolactoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Spironolactone.
StiripentolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Levorphanol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levorphanol.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levorphanol.
SuvorexantThe risk or severity of adverse effects can be increased when Levorphanol is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Levorphanol.
TetrabenazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tetrodotoxin.
ThalidomideLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Levorphanol.
TheobromineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Theobromine.
ThiamylalThe risk or severity of adverse effects can be increased when Levorphanol is combined with Thiamylal.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Levorphanol.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Levorphanol.
ThioridazineThioridazine may increase the hypotensive activities of Levorphanol.
ThioridazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tiagabine.
TicrynafenThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tiletamine.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Levorphanol.
TizanidineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tolcapone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Levorphanol.
TolvaptanThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Levorphanol.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levorphanol.
TrazodoneLevorphanol may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Levorphanol.
TriamtereneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Triazolam.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Levorphanol.
TrifluoperazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Levorphanol.
TriflupromazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Levorphanol.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Levorphanol.
TrimipramineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Triprolidine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Levorphanol.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Levorphanol.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Levorphanol.
UlaritideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ularitide.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Levorphanol.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Levorphanol.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Levorphanol.
VigabatrinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Vigabatrin.
VilazodoneLevorphanol may increase the serotonergic activities of Vilazodone.
VortioxetineLevorphanol may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Levorphanol.
XylazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Levorphanol is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ziconotide.
ZimelidineLevorphanol may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Levorphanol.
ZolazepamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Levorphanol.
ZonisamideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Zuclopenthixol.
Food Interactions
  • Take without regard to meals. Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Allen RM, Granger AL, Dykstra LA: The competitive N-methyl-D-aspartate receptor antagonist (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959) potentiates the antinociceptive effects of opioids that vary in efficacy at the mu-opioid receptor. J Pharmacol Exp Ther. 2003 Nov;307(2):785-92. Epub 2003 Sep 15. [PubMed:12975489 ]
  2. Prommer E: Levorphanol: the forgotten opioid. Support Care Cancer. 2007 Mar;15(3):259-64. Epub 2006 Oct 13. [PubMed:17039381 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Prommer E: Levorphanol: the forgotten opioid. Support Care Cancer. 2007 Mar;15(3):259-64. Epub 2006 Oct 13. [PubMed:17039381 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Prommer E: Levorphanol: the forgotten opioid. Support Care Cancer. 2007 Mar;15(3):259-64. Epub 2006 Oct 13. [PubMed:17039381 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23